98%
921
2 minutes
20
Thrombotic diseases represent a significant global health burden, particularly for middle-aged and elderly populations. Medicinal leeches, such as and , have been traditionally used for their anticoagulant properties. The genomes of these leeches each harbor three lefaxin genes, which are designated and , respectively. We conducted genomic and transcriptomic sequencing on wild populations of both species. Bioinformatics tools were employed to analyze intraspecific variation, molecular evolution, and protein structures. We expressed recombinant lefaxin proteins in and assessed their anticoagulant activities using in vitro coagulation assays. exhibited greater genetic diversity and stability, whereas showed higher expression levels and hydrophilicity. Both species exhibited purifying selection, indicating conserved function, and their lefaxin structures are similar to the archetypal lefaxin (UniProt No. P86681.1). lefaxins bound Factor Xa more effectively. lefaxins exhibited more robust anticoagulant activity in vitro compared to those from . , a non-hematophagous leech, shows potent anticoagulant activity through lefaxins, challenging traditional views on leech efficacy. This study underscores the potential of lefaxins as therapeutic targets for thrombotic diseases and highlights the need to reconsider the use of various leech species in medicine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383447 | PMC |
http://dx.doi.org/10.3390/biology14080918 | DOI Listing |
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFRev Med Interne
September 2025
Service d'hématologie biologique, CHU d'Amiens-Picardie, Amiens, France; HEMATIM UR4666, université Picardie Jules-Verne, Amiens, France.
The diagnosis of hemolysis is still based on straightforward biochemical parameters: haptoglobin (the most sensitive), lactate dehydrogenase (LDH), and unconjugated bilirubin. Anemia is not always present. Reticulocyte counts typically exceed 120×10/L, except in cases of associated vitamin deficiency or during the very early phase of acute hemolysis.
View Article and Find Full Text PDFPhysiol Rep
September 2025
Univ. Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France.
Temperature-sensitive Transient Receptor Potential (TRP) channels contribute to modulating skin vascular tone. Their role in Raynaud's Phenomenon (RP) remains unknown. We aimed to investigate TRPs expression in the skin, along with microvascular reactivity to cooling in patients with primary and secondary RP, compared with healthy subjects.
View Article and Find Full Text PDFBMJ Case Rep
September 2025
Cardiology, JIPMER, Puducherry, India.
A left ventricular sub-mitral thrombus without an aneurysm is a previously unreported rare occurrence. We aim to bring attention to this finding in a case of colorectal adenocarcinoma.An early 60s-year-old female presented with bleeding per rectum, weight loss and fatigue and was found to have colorectal carcinoma with metastasis based on examination, imaging and biopsy findings.
View Article and Find Full Text PDFJACC Cardiovasc Interv
September 2025
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Background: Previous trials have demonstrated increased 5-year risks for adverse clinical events after coronary artery implantation of poly-l-lactic acid-based bioresorbable scaffolds (BRS) compared with cobalt chromium (CoCr) everolimus-eluting stents (EES).
Objectives: The aim of this study was to evaluate the 5-year clinical outcomes of the novel sirolimus-eluting NeoVas BRS compared with CoCr EES.
Methods: A total of 560 patients with single de novo native coronary artery lesions with reference vessel diameter 2.